NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) has reported its full-year financial results for 2025 and provided a corporate update. The company reported having $728.9 million in cash, cash equivalents, and marketable securities at the end of December 2025, a decrease from $834.2 million at the end of 2024.
The company recognized $22.5 million in revenue for the year ended December 31, 2025, down from $45.6 million in the previous year. The decrease in revenue was partially offset by an increase in the amount of revenue recognized in the current period related to the development cost contributions under the Menarini license.
Research and development (R&D) expenses for the year ended December 31, 2025, were $141.8 million, compared to $151.4 million in the previous year. Selling, general, and administrative (SG&A) expenses increased to $106.4 million for the year ended December 31, 2025, from $70.4 million in the year ended December 31, 2024.
The net loss for the year ended December 31, 2025, was $203.8 million, a decrease from a net loss of $241.6 million in the previous year.
NewAmsterdam is focused on developing obicetrapib, an oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor, as a monotherapy and in fixed-dose combination with ezetimibe. The company announced that approval decisions from the European Medicines Agency (EMA), UK, and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed-dose combination are expected in the second half of 2026. The company also provided updates on its clinical development and regulatory activities, including the initiation of the Rubens phase 3 trial and plans to initiate a new clinical trial evaluating obicetrapib in early Alzheimer’s disease patients in 2026.
NewAmsterdam highlighted its progress in advancing obicetrapib and its financial strength, with cash runway expected to be sufficient to fund operations through the Prevail readout and, if approved, support the subsequent U.S. commercial launch.
The company's CEO, Michael Davidson, emphasized the company's mission to bring a potentially transformative therapy with obicetrapib to cardiometabolic disease patients who struggle to reach their LDL-C goals. He also mentioned the company's efforts to expand its commercial capabilities and execute its clinical development strategy.
The press release also provided insights into the ongoing phase 3 trials and upcoming milestones related to obicetrapib and the fixed-dose combination with ezetimibe.
NewAmsterdam's financial results and corporate update indicate its continued focus on advancing its pipeline and pursuing regulatory approvals while maintaining financial discipline and operational efficiency. Following these announcements, the company's shares moved -0.57%, and are now trading at a price of $31.65. For the full picture, make sure to review NewAmsterdam Pharma Co's 8-K report.
